ALDX (Aldeyra Therapeutics, Inc.) Stock Financials & Earnings

ALDXAldeyra Therapeutics, Inc.

Mkt Cap$318M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$34M

EPS (TTM)-$0.57

Free Cash Flow (TTM)$28.2T

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$17M
Q2 23	$0	$0	-$10M
Q3 23	$0	$0	-$10M
Q4 23	$0	-$66K	-$6M
Q1 24	$0	$0	-$9M
Q2 24	$0	$0	-$18M
Q3 24	$0	$0	-$16M
Q4 24	$0	-$64K	-$17M
Q1 25	$0	$0	-$10M
Q2 25	$0	$0	-$10M
Q3 25	$0	$0	-$8M
Q4 25	$0	-$65K	-$7M

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$11M	$6M	—
Q2 23	$7M	$3M	—
Q3 23	$7M	$3M	—
Q4 23	$4M	—	$2M
Q1 24	$6M	$3M	—
Q2 24	$15M	$3M	—
Q3 24	$12M	$4M	—
Q4 24	$15M	—	$2M
Q1 25	$7M	$3M	—
Q2 25	$9M	$2M	—
Q3 25	$5M	$3M	—
Q4 25	—	—	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$165M	$0	$165M
Q2 23	$152M	$0	$152M
Q3 23	$143M	$0	$143M
Q4 23	$143M	$0	$143M
Q1 24	$102M	$31M	$133M
Q2 24	$71M	$49M	$120M
Q3 24	$68M	$45M	$113M
Q4 24	$55M	$47M	$101M
Q1 25	$50M	$40M	$90M
Q2 25	$41M	$41M	$82M
Q3 25	$59M	$16M	$75M
Q4 25	$70.0T	$0	$70.0T

Shares Outstanding

Revenue Per Employee

Revenue / Employee